| Literature DB >> 33665510 |
Rick Xing Ze Lu1, Milica Radisic1,2,3,4.
Abstract
Despite showing a great promise in the field of nanomedicine, nanoparticles have gained a significant attention from regulatory agencies regarding their possible adverse health effects upon environmental exposure. Whether those nanoparticles are generated through intentional or unintentional means, the constant exposure to nanomaterials can inevitably lead to unintended consequences based on epidemiological data, yet the current understanding of nanotoxicity is insufficient relative to the rate of their emission in the environment and the lack of predictive platforms that mimic the human physiology. This calls for a development of more physiologically relevant models, which permit the comprehensive and systematic examination of toxic properties of nanoparticles. With the advancement in microfabrication techniques, scientists have shifted their focus on the development of an engineered system that acts as an intermediate between a well-plate system and animal models, known as organ-on-a-chips. The ability of organ-on-a-chip models to recapitulate in vivo like microenvironment and responses offers a new avenue for nanotoxicological research. In this review, we aim to provide overview of assessing potential risks of nanoparticle exposure using organ-on-a-chip systems and their potential to delineate biological mechanisms of epidemiological findings.Entities:
Keywords: Nanoparticles; Organ-on-a-chip; Toxicity
Year: 2021 PMID: 33665510 PMCID: PMC7900603 DOI: 10.1016/j.bioactmat.2021.01.021
Source DB: PubMed Journal: Bioact Mater ISSN: 2452-199X
Fig. 1Presence of nano and micro particles in the environment and their possible effects on human health. (A) Routes of exposure, distribution, and the subsequent effects of air pollution and plastic pollution on human health outcome. (B) Size comparisons for air pollution particulate matter and plastic pollution. Microplastic can undergo continuous fragmentation to form nanoplastic. (C) The matrix representing the number of impacts of pollution debris in peer reviewed literature. Red squared region represents lack of toxicological studies in biological settings on the nano-meter scale. (For interpretation of the references to colour in this figure legend, the reader is referred to the Web version of this article.)
Effect of nanoparticles on modulating cellular and organ functions.
| Findings | Nanoparticle | Model | Results | References |
|---|---|---|---|---|
| 20–29 nm Carbon Black | Rats Inhalation | Significant amount of carbon nanoparticle accumulation was observed in the liver after 1 day of exposure. | [ | |
| 3.8 nm Gold nanoparticles | Human Inhalation | Gold nanoparticles are detected in the blood and urine after 15 min of exposure. At least 0.2% of inhaled nanoparticles translocated from the lung into circulation. | [ | |
| 10–250 nm Gold nanoparticles | Rats Intravenous | Biodistribution of nanoparticles is size dependent. Smaller nanoparticles are found in blood, liver, spleen, kidney, heart, lungs, and brain, whereas the larger particles are only found in blood, liver, and spleen. | [ | |
| 200 nm PS particles | Mice Inhalation | PS nanoparticles are found to enter extrapulmonary organs, such as liver and kidneys, through the air-blood-barrier in the acinar region. | [ | |
| 100–3000 nm PS particles | Rats Gavage | PS nanoparticles can cross gastrointestinal barrier and translocate into the liver, blood, and bone marrow. | [ | |
| UFP | Mice Inhalation | Exposure of UFP for 3 months damage 50% of lung tissues, as marked by alveolar wall thickening, macrophage infiltration, and cystic lesion. | [ | |
| 20 nm Nickel Oxide | Rats Intratracheal instillation | Lung injury is marked by a constant increase of MIP-1α expression, and transient expression increase of IL-1α, IL-1β, and MCP-1. | [ | |
| 46.5 nm CuO nanoparticles | Mice Intranasal | CuO nanoparticles instigate acute lung toxicity through DNA damage, reactive oxygen species (ROS) generation, and secretion of proinflammatory cytokines, which promotes pulmonary fibrosis as marked by myofibroblast activation and collagen deposition. | [ | |
| ~30 nm Polyacrylate nanoparticles | Human | Nanoparticle exposure leads to shortness of breath and pleural effusion, which leads to complications including pulmonary inflammation, inflammatory infiltration, pulmonary fibrosis, and foreign-body granulomas of the pleura. | [ | |
| 15- and 46 nm SiO2 nanoparticles | A549 | Nanoparticle treatment causes ROS generation, increase in LDH, lipid peroxidation and membrane damage. | [ | |
| 10- and 50 nm SiO2 nanoparticles | BEAS-2B HBEC3-KT | Nanoparticles exposure induces the secretion of IL-6 and CXCL-8, which lead to cell necrosis through p38-phosphorylation, TACE-mediated transforming growth factor (TGF)-α release and NF-κB activation | [ | |
| 14 nm Carbon black nanoparticles | HUVEC Aorta Segments | Activate endothelial cells through increase in intercellular adhesion molecule-1 (ICAM-1)/vascular adhesion molecule (VCAM)-1 expression and ROS, which lead to vasomotor dysfunction. | [ | |
| 100 nm TiO2 nanoparticles | Rats Inhalation | Inhalation of nanoparticles impair vasodilator capacity in the systemic microcirculation. | [ | |
| UFP <180 nm | Mice Inhalation | Exposure to UFP induces early sign of atherosclerosis, which is instigated by the systemic oxidative stress and interference with the anti-inflammatory capacity of plasma high density lipoprotein. | [ | |
| 22 nm Fe2O3 | HAEC U937 Cells | Nanoparticle exposure leads to adhesion of U937 to the HAEC due to the upregulation of ICAM-1 and IL-8, which are an early sign of atherosclerosis. | [ | |
| 23.5 nm TiO2 nanoparticles | HMVEC | Small nanoparticles promote vascular leakiness through binding to VE-cadherin and disrupt cell-cell interaction through activation of actin-rearrangement pathway without generating ROS. | [ | |
| Various nanoparticles | HUVEC | Exposure to nanoparticles increase the level of intracellular ROS and activate catalase, which disrupt VE-cadherin adherents junction. | [ | |
| 38 nm TiO2 nanoparticles | Rats Intratracheal Instillation | Exposure to nanoparticles leads to irreversible cardiac function and structural remodeling of hypertensive heart. | [ | |
| 62 nm SiO2 nanoparticles | Zebrafish | Induces pericardial edema and bradycardia through inhibition of calcium signaling pathway and cardiac muscle contraction pathway via the downregulation of proteins related to ATPase, calcium channel, and cardiac troponin C. | [ | |
| 7- and 670 nm SiO2 nanoparticles | Isolated rat cardiomyocytes | Nanoparticles interfere with cardiac function through impairment of Ca2+ handling and reduction in cell shortening which is caused by mitochondrial malfunction. | [ | |
| 60 nm SiO2 nanoparticles | H9C2 Rat Cardiomyocytes | Nanoparticles inhibit gap junction cellular communication through downregulation of connexin-43, causing cell death through mitochondrial pathway-related apoptosis. | [ | |
| 25–35 nm TiO2 nanoparticles | Rats Intratracheal Instillation | Acute nanoparticle exposure increases cardiac conduction velocity and changes cellular electrophysiology, thereby increasing propensity of inducible arrhythmia. | [ | |
| TiO2 SiO2 | Guinea Pig Langendorff Heart | Perfusion of nanoparticles causes ST elevation and increase in heart rate by a release of catecholamines from the sympathetic nerve ending. | [ | |
| UFP | Mice Oral Administration | Ingestion of UFP alters gut microbiota composition, which is caused by increased atherogenic lipid metabolites. | [ | |
| PM2.5 | Mice Gavage | PM2.5 increases intestinal permeability, which is caused by disruption of tight junction proteins (ZO-1) and upregulation of inflammatory IL-6. | [ | |
| 50 nm carboxylated PS nanoparticles | Caco2/HT29-MTX Chicken Oral Administration | Nanoparticle exposure decreases permeability of intestinal cell layer, which disrupts iron transport. Acute oral exposure of PS nanoparticles disrupt iron transport while chronic exposure increases iron absorption through remodeling of the intestinal villi | [ | |
| 500 nm PS particles | Mice Oral Administration | Oral administration of PS particles decrease the secretion of mucus and change the diversity of gut microbiota in the cecum | [ | |
| 44- and 100 nm PS nanoparticles | Human gastric adenocarcinoma cells | Nanoparticle exposure induces an upregulation of IL-6 and IL-8 genes. | [ | |
| PM2.5 | Murine Inhalation | PM2.5 induces hepatic fibrosis in mice through activation of TGF-β/SMAD3 signaling pathway and suppression of peroxisome proliferator activated receptor γ. | [ | |
| PM2.5 | Mice Inhalation | Disrupt liver functions such as insulin resistance, hyperlipidemia, and glucose tolerance through upregulation of inflammatory factors which in turn increase oxidative damage and accumulation of lipid in the liver. | [ | |
| 80 nm Cu nanoparticles | Rats Oral Administration | Induces oxidative stress and upregulates secretion of proinflammatory cytokines (IL-2, IL-6, IFN-γ, MIP-1), leading to liver metabolism malfunction by inhibiting various CYP450 enzymes. | [ | |
| TiO2 nanoparticles | Mice Intragastric Administration | Nanoparticles causes histopathological changes and hepatocyte apoptosis through upregulation of inflammatory cytokines (IKK1, IKK2, NF-κB, TNF-α, and NIK) and increase in the blood serum of ALT, ASP, ALP, and LDH. | [ |
Organ-on-a-chip system for studies of nanoparticle induced toxicity.
| Model | Nanoparticle | Device Materials | Cell Type | Key Findings/Significance | References |
|---|---|---|---|---|---|
| 100 nm Au nanoparticles | Ibidi polymer coverslip | HUVEC | Nanoparticle uptake into the endothelial cells is flow dependent, with increased flow leading to a decreased nanoparticle uptake | [ | |
| 40–60 nm inhaled atmospheric nanoparticles (ANP) | PDMS | HUVEC/human pulmonary fibroblast | Exposure to ANP results in vascular dysfunction, which is correlated with increased level of pro-inflammatory biomarkers and intracellular Ca2+ influx, and an imbalance in the nitric oxide and entothelin-1 | [ | |
| 6.5 nm Au nanoparticles | PDMS | HUVEC | Perfusion of Au nanoparticles reduces sedimentation of nanoparticle aggregates onto the cells and lowers cytotoxic effects compared to the level measured in a static platform | [ | |
| 12 nm Silica nanoparticle | PDMS | Human alveolar epithelial cells/microvascular endothelial cells | Cyclic motion promotes higher ROS production and nanoparticle translocation Demonstration of a complex multi-step epithelial-endothelial crosstalk as marked by the activation of ICAM-1 activation | [ | |
| Cigarette Smoke | PDMS | Primary human small airway epithelial cells | Identifies 10 molecular signatures that are responsible for chronic obstructive pulmonary disease upon exposure to cigarette smoke | [ | |
| Carbon nanotubes | PDMS | BEAS-2B lung epithelial cells | Low dose of carbon nanotubes leads to early sign of pulmonary fibrosis, as illustrated by the increase of tissue contraction force and upregulation of fibrogenic marker miR-21 expression | [ | |
| 20 nm TiO2 nanoparticles | Gelatin/PDA + PCL nanofiber | Neonatal rat ventricular myocyte | Treatment of TiO2 nanoparticles lowers cardiac tissue function through impairment of calcium transient propagation and disruption of sarcomere structure | [ | |
| 50 nm CuO and SiO2 nanoparticles | PDMS | HUVEC/iPSC-derived cardiomyocytes | Perfusion of nanoparticles leads to nanoparticle translocation from endothelium to the cardiac tissue, which lead to cardiac tissue electrical and contractile dysfunction through generation of ROS and secretion of biomarkers associated with cardiac injury (BNP, NP-proBNP, and troponin I) | [ | |
| 50 nm carboxylated PS nanoparticles | Silicon/plexiglass | Caco-2/HT29-MTX + HepG2/C3A | Gut/liver chip model demonstrates compounding effects of inter-organ crosstalk between gut and the liver in facilitating nanoparticle toxicity as illustrated by the significantly higher AST release | [ | |
| 10 nm Fe3O4 nanoparticles | PDMS/Glass | Rat hepatocyte | Perfusion of Fe3O4 nanoparticles results in the reduction of albumin and urea production, indicating potential liver injury. | [ |
Fig. 2Development of microfluidic devices to understand nanoparticle-induced vascular dysfunction. (A) A single microfluidic device connected to a peristatic pump for controlled perfusion (top left). Increased shear stress reduces nanoparticle uptake (top right). Fluorescent images of nanoparticles (white) revealed that nanoparticle cellular uptake stabilized after 36 h of exposure at a flow rate of 5 ml/min (bottom). Reproduced with permission [27]. Copyright 2020, John Wiley and Sons. (B) Hydrogel based microvasculature-on-a-chip system for investigation of different modes of endothelial barrier dysfunction (top). Upon TNF-α stimulation, adhesion molecules such as E-selectin, VCAM-1, and ICAM-1 were upregulated (middle), which increased the permeability of engineered microvasculature as indicated by leakage of BSA-AF594 (bottom). Reproduced with permission [28]. Copyright 2018, Springer Nature. (C) Microfluidic device featuring microfluidic posts to permit the diffusion of nanoparticles (top left). pCRT-cAMP was added to reduce vascular paracellular permeability by promoting expression of adherens junctions (right) to model normal vasculature. Upon exposure of fluorescent PS nanoparticles, the permeability of nanoparticles across untreated leaky vasculature decreased with increased particle size, while permeability did not change for pCRT-cAMP treated vasculature [150]. Copyright 2017, Springer Nature. (D) A microfluidic device integrated TEER sensor to probe nanoparticle translocation (top). TNF-α treatment caused decrease in vascular barrier function as marked by decrease in TEER, which in turn increased nanoparticle translocation (bottom left). TEER measurement and nanoparticle translocation is inversely correlated (bottom right).
Fig. 3Representative lung-on-a-chip systems that can be used to understand nanoparticle induced toxicity. (A) Schematic of a human breathing lung-on-a-chip to study the effect of cyclic mechanical strain on nanoparticle translocation and phenotypic ROS generation. Reproduced with permission [29]. Copyright 2010, The American Association for the Advancement of Science. (B) Schematic of lung-on-a-chip system to study the onset of pulmonary edema (interstitial fluid buildup) upon IL-2 stimulation.
Reproduced with permission [181]. Copyright 2012, The American Association for the Advancement of Science.
(C) Recapitulation of fibrogenesis in lung microtissue. Continuous TGF-β treatment induced increase in the expression of α-SMA, pro-collagen, and EDA-Fibronectin compared to untreated microtissue [185]. Copyright 2018, Springer Nature. (D) Photograph of vascularized alveolar model printed by 3D stereolithography technique. Red blood cells are perfused to demonstrate oxygenation and deoxygenation. Reproduced with permission [187]. Copyright 2019, The American Association for the Advancement of Science.
Fig. 4Representative heart-on-a-chip systems for understanding nanoparticle induced toxicity. (A) Matured cardiac tissue for investigation of cardiac fibrosis (left). Fibrotic tissue exhibited higher expression of vimentin (green) as illustrated in the immunostaining image of cardiac and fibrotic tissue (right). Reproduced with permission [205]. Copyright 2019, American Chemical Society. (B) Fibrin-coated cardiac microphysiological device for contractility assessment. Exposure to TiO2 nanoparticles decreased contractile function of cardiac tissue through disruption of sarcomeric structure. Reproduced with permission [208]. Copyright 2018, Springer Nature. (C) Confocal image of perfusable vascularized scaffold that supports the self-assembly of cardiac tissue (red: CD31, green: sarcomeric α-actinin). This system allows the investigation of complex interaction between endothelial cells and nanoparticles, and their subsequent cardiac toxicity under electrical stimulation in 96-well format. Reproduced with permission [131]. Copyright 2017, Advanced Functional Materials. (D) 3D bioprinted neonatal-scale human heart with multi-scale vasculature composed of collagen material (left). Perfusion of glycerol (red) through coronary artery also permits the perfusion down to vessels ~100 μm in diameter (right). (For interpretation of the references to colour in this figure legend, the reader is referred to the Web version of this article.)
Fig. 5Representative gut-on-a-chip systems for understanding nanoparticle induced toxicity. (A) A primary human small intestine-on-a-chip using biopsy-derived organoid. Mucine producing cells (Muc5AC: green) are primarily found along the apical regions of the villi-like structure [31]. Copyright 2018, Springer Nature. (For interpretation of the references to colour in this figure legend, the reader is referred to the Web version of this article.)
Fig. 6Representative liver-on-a-chip systems for understanding nanoparticle induced toxicity. (A) Schematic of the body-on-a-chip system to study inter-organ level crosstalk. Treatment of 50 nm carboxylated PS nanoparticles induced AST in the medium. Reproduced with permission [236]. Copyright 2014, Royal Society of Chemistry. (B) Integration of 3D vascularized hepatic organoid in a microfluidic system (top left). Co-culture of hepatocytes and endothelial cells under flow stimulates drug metabolic process, xenobiotic metabolic process, and the response to drugs (top right), as well as albumin expression (bottom). Reproduced with permission [237]. Copyright 2018, John Wiley and Sons. (C) Schematic of liver-on-a-chip featuring complex liver cytoarchitecture (top). Addition of experimental drug (FIAU) induced the appearance of significant lipid droplets in a human liver-chip but no droplets were observed in rat liver-chip, illustrating species differences in steatosis after FIAU treatment (bottom).